September 30, 2020Open Access

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Key Points

Key points are not available for this paper at this time.

Abstract

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type. (Funded by F. Hoffmann-La Roche/Genentech; IMpower110 ClinicalTrials.gov number, NCT02409342.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Roy S. Herbst

Giuseppe Giaccone

Filippo de Marinis

Journals

New England Journal of Medicine

Actions

Institutions

Cornell University

Yale University

Nagoya University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study